Option chain shows key data for NovaBay Pharmaceuticals's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for NovaBay Pharmaceuticals.

NovaBay Pharmaceuticals (AMEX:NBY) Stock, Option Chain

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals Inc is a biopharmaceutical company that develops and sells scientifically-created and clinically eyecare and skincare products. Its product, Avenova Antimicrobial Lid and Lash Solution (Avenova Spray), is laboratory tested to have broad antimicrobial properties as it removes foreign material including microorganisms and debris from the skin around the eye, including the eyelid. Avenova Spray is available directly to consumers through online distribution channels and is also often prescribed and dispensed by eyecare professionals for blepharitis and dry-eye disease. It has two reportable segments: Eyecare and Wound Care and Skincare.

Medicine

News

Movers

NovaBay shares are trading higher after the company announced it reached a definitive agreement to sell its Avenova assets for $9.5 million to Physician Recommended Nutraceuticals.

What&#39;s Going On With NovaBay Pharmaceuticals Shares Friday?

vaccine-4892048

NovaBay Pharmaceuticals shares are lower by 66% over the trailing five sessions. The company last week announced the pricing of its public offering.

What&#39;s Going On With NovaBay Pharmaceuticals (NBY) Stock?

Earnings

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

COUR

DXCM

NMHI

WINT

S&amp;P 500 Gains Over 1%; 3M Shares Jump After Q2 Results

NovaBay Pharmaceuticals, Inc. Common Stock

NovaBay Pharmaceuticals Inc

Niobay Metals Inc

<h3>Gainers</h3>
<ul>
<li>Agape ATP (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ATPC#NASDAQ">ATPC</a>) shares increased by 81.0% to $2.28 during Monday's pre-market session. The company's market cap stands at $9.0 million. </li>
<li>Sage Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAGE#NASDAQ">SAGE</a>) shares moved upwards by 36.93% to $7.6. The company's market cap stands at $464.9 million. </li>
<li>Intra-Cellular Therapies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITCI#NASDAQ">ITCI</a>) shares rose 35.56% to $128.61. The company's market cap stands at $13.6 billion. </li>
<li>GlucoTrack (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GCTK#NASDAQ">GCTK</a>) stock rose 32.73% to $0.16. The market value of their outstanding shares is at $2.4 million. </li>
<li>CytoMed Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDTC#NASDAQ">GDTC</a>) stock moved upwards by 27.53% to $3.52. The market value of their outstanding shares is at $40.6 million. </li>
<li>GT Biopharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GTBP#NASDAQ">GTBP</a>) shares increased by 26.03% to $3.34. The market value of their outstanding shares is at $7.4 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Ocular Therapeutix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OCUL#NASDAQ">OCUL</a>) stock fell 14.7% to $7.0 during Monday's pre-market session. The company's market cap stands at $1.1 billion. </li>
<li>Indaptus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INDP#NASDAQ">INDP</a>) shares declined by 13.69% to $0.82. The market value of their outstanding shares is at $9.8 million. </li>
<li>Aligos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALGS#NASDAQ">ALGS</a>) shares decreased by 12.7% to $29.43. The market value of their outstanding shares is at $105.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock fell 12.49% to $0.61. The market value of their outstanding shares is at $2.9 million. </li>
<li>AirSculpt Technologies (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIRS#NASDAQ">AIRS</a>) stock declined by 12.21% to $5.25. The company's market cap stands at $303.8 million. </li>
<li>NAYA Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NAYA#NASDAQ">NAYA</a>) stock declined by 12.11% to $0.71. The market value of their outstanding shares is at $3.5 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AIRS

ALGS

ATPC

GCTK

GDTC

GTBP

INDP

ITCI

NAYA

OCUL

SAGE

12 Health Care Stocks Moving In Monday's Pre-Market Session

General

NovaBay Pharma shares are trading lower after the company announced the sale of its Wound Care Trademarks for $500K.

Asset Sales

NovaBay Pharmaceuticals Sells Wound Care Trademarks NeutroPhase, PhaseOne, And OmniPhase To Phase One Health For $500K

Initial meeting adjourned due to insufficient votes to reach the 50% threshold of outstanding common shares voting in favor of Proposal One and Proposal Two
Stockholders who have not voted are strongly encouraged to vote FOR Proposal One and Proposal Two
NovaBay&#xAE; Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) ("NovaBay" or the "Company") announces that its Special Meeting of Stockholders held on November 22, 2024 has been adjourned until December 18, 2024 at 11:00 a.m. Pacific time to provide stockholders additional time to vote on Proposal One and Proposal Two. Both proposals received significant support based on the shares that have been voted by stockholders but have yet to reach the 50% threshold of favorable votes of all outstanding shares of common stock required to approve each proposal.
<ul>
<li>Proposal One is a proposal to approve the sale of Avenova, representing substantially all of the assets of the Company (the "Asset Sale"), pursuant to the Asset Purchase Agreement, dated September 19, 2024, by and between the Company and PRN Physician Recommended Nutriceuticals, LLC.
<ul>
<li>Proposal Two is a proposal to approve the liquidation and dissolution of the Company, pursuant to the Plan of Complete Liquidation and Dissolution of the Company (the "Plan of Dissolution") which, if approved, would authorize the Company to liquidate and dissolve in accordance with the Plan of Dissolution, and pursuant to the discretion of the Board of Directors to proceed with the dissolution.</li>
</ul>
</li>
</ul>

NovaBay Pharmaceuticals To Reconvene Special Meeting Of Stockholders To December 18, 2024; Initial Meeting Adjourned Due To Insufficient Votes To Reach The 50% Threshold Of Outstanding Common Shares Voting In Favor Of Proposal One And Two

Ascendiant Capital analyst Edward Woo maintains NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) with a Buy, adjusts target to $0.85 from $8 (1-35 Reverse Stock Split).

Price Target

Analyst Ratings

Ascendiant Capital Maintains Buy on NovaBay Pharmaceuticals, Adjusts Price Target To $0.85 (1-35 Reverse Stock Split)

NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) reported quarterly losses of $(0.60) per share which missed the analyst consensus estimate of $(0.30) by 100 percent. This is a 95.42 percent increase over losses of $(13.11) per share from the same period last year. The company reported quarterly sales of $2.44 million which missed the analyst consensus estimate of $2.62 million by 6.94 percent. This is a 1.61 percent decrease over sales of $2.48 million the same period last year.

Earnings Misses

NovaBay Pharmaceuticals Q3 EPS $(0.60) Misses $(0.30) Estimate, Sales $2.44M Miss $2.62M Estimate

<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.novabay.com%2F&amp;esheet=54148290&amp;newsitemid=20241106147268&amp;lan=en-US&amp;anchor=NovaBay%26%23174%3B+Pharmaceuticals%2C+Inc&amp;index=1&amp;md5=40d730c218a86212338151c7b806277c">NovaBay&#xAE; Pharmaceuticals, Inc</a>. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) ("NovaBay" or the "Company") today announces that the Company has accepted a revised transaction proposal from PRN Physician Recommended Nutriceuticals, LLC ("PRN") to increase the base purchase price for the Company's eyecare business from $9.5 million to $11.5 million. The Company has entered into an amendment (the "Amendment") to its previously announced Asset Purchase Agreement, dated September 19, 2024, with PRN (the "Original PRN APA" and, as amended, the "PRN APA"). The Company's transaction with PRN remains subject to certain closing conditions, including receiving stockholder approval.

NovaBay Pharmaceuticals Accepts Revised Offer From PRN Physician Recommended Nutriceuticals, LLC And Enters Into An Amendment To The Asset Purchase Agreement To Increase Purchase Price From $9.5M To $11.5M

WIIM

NovaBay Pharmaceuticals shares are trading higher after the company announced it received an acquisition offer for up to $11.5 million, which is superior to the previous offer from a different entity.

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) stock rose 147.9% to $0.42 during Tuesday's pre-market session. The market value of their outstanding shares is at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock rose 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) shares moved upwards by 55.73% to $2.04. The market value of their outstanding shares is at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock increased by 52.83% to $0.84. The company's market cap stands at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) stock increased by 29.53% to $2.5. The market value of their outstanding shares is at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) stock increased by 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) stock declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the press release, Q3 earnings came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) stock declined by 19.18% to $0.25. The market value of their outstanding shares is at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) stock decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) shares decreased by 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) stock decreased by 14.41% to $8.5. The company's market cap stands at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The market value of their outstanding shares is at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

AMWL

BIOR

Cardio Diagnostics Holdings Inc. - Common stock

CDIO

GLYC

HCTI

IMRN

LIXT

PTIX

SHPH

TMDX

TRIB

12 Health Care Stocks Moving In Tuesday's Pre-Market Session

<h3>Gainers</h3>
<ul>
<li>GlycoMimetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLYC#NASDAQ">GLYC</a>) shares increased by 147.9% to $0.42 during Tuesday's pre-market session. The company's market cap stands at $26.8 million. </li>
<li>Shuttle Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SHPH#NASDAQ">SHPH</a>) stock moved upwards by 56.39% to $2.08. The market value of their outstanding shares is at $6.1 million. </li>
<li>Lixte Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LIXT#NASDAQ">LIXT</a>) stock rose 55.73% to $2.04. The company's market cap stands at $4.5 million. </li>
<li>NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) stock rose 52.83% to $0.84. The market value of their outstanding shares is at $4.1 million. </li>
<li>Immuron (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRN#NASDAQ">IMRN</a>) shares moved upwards by 29.53% to $2.5. The company's market cap stands at $14.2 million. </li>
<li>Protagenic Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PTIX#NASDAQ">PTIX</a>) shares rose 22.44% to $0.69. The market value of their outstanding shares is at $3.0 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>TransMedics Gr (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TMDX#NASDAQ">TMDX</a>) shares declined by 23.6% to $96.46 during Tuesday's pre-market session. The market value of their outstanding shares is at $3.2 billion. As per the news, the Q3 earnings report came out yesterday. </li>
<li>Cardio Diagnostics Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDIO#NASDAQ">CDIO</a>) shares declined by 19.18% to $0.25. The company's market cap stands at $7.7 million. </li>
<li>Biora Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIOR#NASDAQ">BIOR</a>) shares decreased by 16.97% to $3.67. The company's market cap stands at $13.4 million. </li>
<li>Trinity Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TRIB#NASDAQ">TRIB</a>) stock fell 15.01% to $1.87. The company's market cap stands at $17.7 million. </li>
<li>American Well (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMWL#NYSE">AMWL</a>) shares fell 14.41% to $8.5. The market value of their outstanding shares is at $127.4 million. </li>
<li>Healthcare Triangle (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCTI#NASDAQ">HCTI</a>) shares fell 13.08% to $1.13. The company's market cap stands at $6.4 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

NovaBay Pharmaceuticals Determines Unsolicited Offer From Refresh Acquisitions BidCo For An Affiliate Of Refresh To Acquire The Avenova Brand Is A Superior Proposal To Asset Purchase Agreement With PRN Physician Recommended Nutriceuticals,; Under Refresh Offer, Co. Would Receive Purchase Price Of Up To $11.5M, Subject To A Downside Net Working Capital Adjustment

NovaBay Pharmaceuticals, Inc. (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) shares are trading higher after the company announced it reached a definitive agreement to sell its Avenova assets for $9.5 million to <a href="https://www.benzinga.com/news/24/09/40956105/novabay-pharmaceuticals-reaches-definitive-deal-to-sell-avenova-assets-for-9-5m-expected-to-close-q4">Physician Recommended Nutraceuticals</a>.
The Details: The company expects the transaction to close during the 2024 fourth quarter, pending NovaBay shareholder approval. 
&#8220;I believe we have found an ideal home for Avenova. We expect the brand to continue to grow and flourish under PRN&#8217;s capable leadership and their ability to promote Avenova through their existing network of more than 5,000 eyecare professionals,&#8221; said NovaBay CEO Justin Hall.
&#8220;It&#8217;s gratifying to share that more people are using Avenova than ever before and with the support, resources and synergies that PRN can provide, we expect that number to continue to grow.&#8221;
How To Buy NovaBay Shares
By now you're likely curious about how to participate in the market for NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) &#8211; be it to purchase shares, or even attempt to bet against the company.
Buying shares is typically done through a brokerage account. You can find a list of <a href="https://www.benzinga.com/money/best-stock-trading-platforms">possible trading platforms here.</a> Many will allow you to buy ‘fractional shares,' which allows you to own portions of stock without buying an entire share. For example, some stock, like Berkshire Hathaway, or Amazon.com, can cost thousands of dollars to own just one share. However, if you only want to invest a fraction of that, brokerages will allow you to do so. 
mIf you're looking to bet against a company, the process is more complex. You'll need access to an options trading platform, or a broker who will allow you to ‘go short' a share of stock by lending you the shares to sell. The process of shorting a <a href="https://www.benzinga.com/money/how-to-short-a-stock">stock can be found at this resource.</a> Otherwise, if your broker allows you to trade options, you can either buy a put option, or sell a call option at a strike price above where shares are currently trading &#8211; either way it allows you to profit off of the share price decline.
Related Link: <a href="https://www.benzinga.com/markets/cannabis/24/09/40900626/legal-medical-cannabis-could-save-us-healthcare-29b-annually-new-study-finds">Legal Medical Cannabis Could Save US Healthcare $29B Annually, New Study Finds</a>
NBY Price Action: At the time of writing, NovaBay stock is trading 25.0% higher at 62 cents per data from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Image: Photo by roberto-sorin for Unsplash

What's Going On With NovaBay Pharmaceuticals Shares Friday?

NovaBay Pharmaceuticals shares are trading higher after the company announced it reached a definitive deal to sell its Avenova assets for $9.5 million.

NovaBay Pharmaceuticals Reaches Definitive Deal To Sell Avenova Assets For $9.5M, Expected To Close Q4 2024

NovaBay Pharmaceuticals (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/NBY#AMEX">NBY</a>) reported quarterly losses of $(1.37) per share which missed the analyst consensus estimate of $(1.23) by 11.38 percent. This is a 96.92 percent increase over losses of $(44.43) per share from the same period last year. The company reported quarterly sales of $2.40 million which missed the analyst consensus estimate of $3.15 million by 23.81 percent. This is a 32.09 percent decrease over sales of $3.53 million the same period last year.

NovaBay Pharmaceuticals Q2 EPS $(1.37) Misses $(1.23) Estimate, Sales $2.40M Miss $3.15M Estimate

NovaBay Pharmaceuticals Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) shares are lower by 66% to $0.67 over the trailing five sessions after announcing the pricing of its <a href="https://www.benzinga.com/pressreleases/24/07/b39982871/novabay-pharmaceuticals-announces-pricing-of-3-5-million-underwritten-public-offering">public offering</a> of 3.2 million shares (or pre-funded warrants) and Series F-1, F-2, and F-3 warrants.
Each share (or pre-funded warrant) and associated warrants are priced at $1.10. The Series F-1 warrants expire in five years, the F-2 in six months and the F-3 in one year, all with a $1.10 exercise price.
Ladenburg Thalmann &amp; Co. Inc., the underwriter, has a 45-day option to purchase an additional 477,272 shares and/or warrants for over-allotments. Expected gross proceeds are $3.5 million, or $4.0 million if the over-allotment option is fully exercised, before expenses. 
NovaBay plans to use the funds to redeem outstanding debentures and for general corporate purposes. The offering is expected to close around July 29.
Read Also: <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40015199/oil-prices-remain-under-pressure-despite-rising-middle-east-tensions-a-bearish-tria">Oil Prices Remain Under Pressure Despite Rising Middle East Tensions: Analyst Says Bearish Price Trend On Horizon</a>
<h1 class="wp-block-heading">Is NBY A Good Stock To Buy?</h1>
An investor can make a few decisions when deciding whether a stock is a good buy. In addition to valuation metrics and price action which you can find on Benzinga's quote pages — like <a href="https://www.benzinga.com/quote/NBY">NovaBay Pharmaceuticals</a>&#8216;s page for example — there are factors like whether or not a company pays a dividend or buys a large portion of its stock each quarter.
These are known as capital allocation programs. NovaBay Pharmaceuticals does not pay a dividend, but obviously there are a few ways it can return value to shareholders. Feel free to search Benzinga's <a href="https://www.benzinga.com/calendars/dividends">dividend calendar</a> for the next company due to pay a dividend and determine what kind of yield you can earn for holding a share of the company.
For example, if you're looking to earn an annualized return of 9.16%, you'll need to buy a share of Allspring Inc Opps by Aug. 12, 2024. Once done, you can expect to receive a nominal payout of $0.05 on Sep. 3.
Buyback programs are obviously different and highly variable. A company can approve a buyback program and purchase shares as it sees fit over the course of time in which the buyback was authorized. 
Looking through the latest news on <a href="https://www.benzinga.com/quote/NBY">NovaBay Pharmaceuticals</a> will often yield whether or not the company has approved a buyback program recently. Buyback programs usually serve as a support for share prices, serving as a backstop for demand.
According to data from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>, NBY has a 52-week high of $44.80 and a 52-week low of $0.64.
Read Next: • <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40016926/markets-brace-for-crucial-interest-rate-shake-up-what-to-expect-from-federal-reserv">Markets Brace For Crucial Interest Rate Shake-Up: What To Expect From Federal Reserve, Bank of Japan, Bank Of England This Week</a>
Photo: Courtesy NBY

What's Going On With NovaBay Pharmaceuticals (NBY) Stock?

U.S. stocks traded higher toward the end of trading, with the S&amp;P 500 gaining more than 1% on Friday.
The Dow traded up 1.66% to 40,598.17 while the NASDAQ rose 1.07% to 17,365.04. The S&amp;P 500 also rose, gaining, 1.17% to 5,462.66.
Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984123/jim-cramer-is-mystified-by-five-below-predicts-crowdstrike-is-going-to-bottom-here"> Jim Cramer Is &#8216;Mystified&#8217; By Five Below, Predicts CrowdStrike &#8216;Is Going To Bottom Here&#8217;</a>
Leading and Lagging Sectors Industrials shares jumped by 2% on Wednesday.
In trading on Wednesday, energy shares rose by just 0.6%.
Top Headline
3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) shares jumped around 21% on Friday after the company posted better-than-expected second-quarter financial results and raised its FY24 EPS outlook.
The company reported second-quarter net sales of $6.255 billion, a slight decline of 0.5% year-over-year. Adjusted net sales totaled $6.019 billion, up 1.1% YoY, beating the consensus of $5.878 billion. Adjusted EPS was $1.93, up from $1.39 in the prior-year quarter, beating the consensus of $1.68.
For fiscal 2024, 3M continues to see adjusted total sales growth of (0.25%) to +1.75% and, on an organic basis, flat to +2%. MMM now expects adjusted EPS of $7.00 – $7.30 (prior $6.80 – $7.30) versus the $7.17 consensus.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares shot up 107% to $6.85 after the company filed a request for the withdrawal of its registration statement on a Form S-1.</li>
<li>Shares of BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) got a boost, surging 144% to $0.5191 after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares were also up, gaining 45% to $10.77 after the company beat second-quarter earnings estimates.</li>
</ul>
Equities Trading DOWN
<ul>
<li>NovaBay Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) shares dropped 64% to $0.70 after the company reported pricing of $3.5 million underwritten public offering.</li>
<li>Shares of DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) were down 42% to $62.50 after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.</li>
<li>Nature&#8217;s Miracle Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) was down, falling 47% to $0.2087 after the company announced pricing of $1.2 million public offering.</li>
</ul>
Also Check This Out: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/39984459/top-3-risk-off-stocks-that-are-set-to-fly-in-july">Top 3 Risk Off Stocks That Are Set To Fly In July</a>
Commodities In commodity news, oil traded down 1.1% to $77.41 while gold traded up 1.2% at $2,381.50.
Silver traded up 0.1% to $28.00 on Friday, while copper fell 0.3% to $4.1145.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.83%, Germany's DAX rose 0.65% and France's CAC 40 rose 1.22%. Spain's IBEX 35 Index rose 0.18%, while London's FTSE 100 rose 1.21%.
Median expectations for inflation over the next 12 months for the Eurozone came in unchanged at 2.8% for June. Spanish unemployment rate declined to 11.27% during the second quarter. The consumer confidence indicator in France climbed to 90.8 in July compared to a revised reading of 89.7 in the prior month.
Asia Pacific Markets
Asian markets closed mostly higher on Friday, with Japan's Nikkei 225 falling 0.53%, Hong Kong's Hang Seng Index gaining 0.1%, China's Shanghai Composite Index gaining 0.14% and India's S&amp;P BSE Sensex jumping 1.62%.
Foreign exchange reserves held by the Reserve Bank of India rose to $670.9 billion as of July 19. The index of coincident economic indicators in Japan rose to 117.1 in May versus a flash reading of 116.5.
Economics
<ul>
<li>The headline Personal Consumption Expenditure (PCE) price index fell to 2.5% year-on-year in June, as expected.</li>
<li>Personal spending in the U.S. rose 0.3% from the prior month in June, while personal income increased by 0.2% to $23.948 trillion in June.</li>
<li>The University of Michigan consumer sentiment was revised higher to 66.4 in July compared to a preliminary level of 66.</li>
<li>The total number of active U.S. oil rigs climbed by 5 to 482 rigs this week, Baker Hughes Inc reported</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/07/39984491/nvidia-lockheed-martin-and-2-other-stocks-insiders-are-selling">Nvidia, Lockheed Martin And 2 Other Stocks Insiders Are Selling</a>

S&P 500 Gains Over 1%; 3M Shares Jump After Q2 Results

NovaBay Pharmaceuticals Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NASDAQ">NBY</a>) shares are trading lower by 62% to $0.73 during Friday&#8217;s session after the company announced the pricing of its public offering of <a href="https://www.benzinga.com/pressreleases/24/07/b39982871/novabay-pharmaceuticals-announces-pricing-of-3-5-million-underwritten-public-offering">3,200,380 shares of common stock</a> (or pre-funded warrants) along with accompanying Series F-1, F-2, and F-3 warrants.
The combined price for each share (or pre-funded warrant) and associated warrants is $1.10. The Series F-1 warrants expire in five years, the F-2 in six months, and the F-3 in one year, each with an exercise price of $1.10 per share. 
The underwriter, Ladenburg Thalmann &amp; Co. Inc., has a 45-day option to purchase up to an additional 477,272 shares and/or warrants to cover over-allotments. 
The total gross proceeds are expected to be around $3.5 million, or $4.0 million if the over-allotment option is fully exercised, before expenses. NovaBay plans to use the proceeds to redeem outstanding debentures and for general corporate purposes. The offering is set to close around July 29.
Read Also: <a href="https://www.benzinga.com/news/24/07/39986346/why-taiwan-semiconductor-manufacturing-company-shares-are-volatile-this-week">Why Taiwan Semiconductor Manufacturing Company Shares Are Volatile This Week</a>
<h2 class="wp-block-heading">Should I Sell My NBY Stock?</h2>
Whether to sell or hold a stock largely depends on an investor's strategy and risk tolerance. Swing traders may sell an outperforming stock to lock in a capital gain, while long-term investors might ride out the turbulence in anticipation of further share price growth.
Similarly, traders willing to minimize losses may sell a stock that falls a certain percentage, while long-term investors may see this as an opportunity to buy more shares at a discounted price.
Investors may also consider market dynamics. The Relative Strength Index can be used to indicate whether a stock is overbought or oversold. NovaBay Pharmaceuticals stock currently has an RSI of 25.04, indicating oversold conditions.
For analysis tools, charting data and access to exclusive stock news, check out <a href="https://pro.benzinga.com/">Benzinga PRO. Try it for free.</a>
NBY has a 52-week high of $44.80 and a 52-week low of $0.74.

Why NovaBay Pharmaceuticals (NBY) Stock Is Down 60%

Shares of Saia, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAIA#NASDAQ">SAIA</a>) fell sharply during Friday's session after the company reported worse-than-expected <a href="https://www.benzinga.com/quote/SAIA/earnings">second-quarter financial results</a>.
Saia reported quarterly earnings of $3.83 per share which missed the analyst consensus estimate of $4.00 per share. The company reported quarterly sales of $823.24 million which missed the analyst consensus estimate of $826.55 million, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
Saia shares dipped 18.6% to $398.01 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>BurgerFi International, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BFI#NASDAQ">BFI</a>) gained 117.4% to $0.4639 after the company announced it reached a legal settlement agreement with Lion Point Capital. The company agreed to pay $1,350,000 and issue Lion Point 300,000 of preferred stock.</li>
<li>Windtree Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WINT#NASDAQ">WINT</a>) shares jumped 101.3% to $6.67 after the company filed a request for the withdrawal of its registration statement on a Form S-1.</li>
<li>Regencell Bioscience Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGC#NASDAQ">RGC</a>) gained 53% to $13.94.</li>
<li>Coursera, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COUR#NYSE">COUR</a>) shares gained 46.2% to $10.83 after the company beat second-quarter earnings estimates.</li>
<li>Carbon Revolution Public Limited Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CREV#NASDAQ">CREV</a>) shares climbed 43.3% to $8.84. Carbon Revolution said it will supply the carbon fiber wheels available on the just-revealed Chevrolet Corvette ZR1.</li>
<li>Everi Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EVRI#NYSE">EVRI</a>) rose 41.1% to $12.93 after it entered an agreement to be acquired by funds managed by Apollo affiliates for $14.25 per share in cash.</li>
<li>Nauticus Robotics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KITT#NASDAQ">KITT</a>) gained 37% to $4.45.</li>
<li>Newell Brands Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NWL#NASDAQ">NWL</a>) jumped 36.6% to $8.66 on better-than-expected second-quarter earnings and raising FY24 outlook.</li>
<li>Sangamo Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SGMO#NASDAQ">SGMO</a>) gained 35% to $0.9043.</li>
<li>CEL-SCI Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVM#NYSE">CVM</a>) rose 28% to $1.55 after the company announced results from a bias analysis conducted for its concluded Phase 3 study of Multikine. Multikine cut the 5-year risk of death by half compared to control in its target population.</li>
<li>AudioEye, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AEYE#NASDAQ">AEYE</a>) rose 25% to $24.52 following second-quarter results.</li>
<li>Pineapple Financial Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PAPL#NYSE">PAPL</a>) gained 24.4% to $1.1760. Pineapple Financial CSO Christa Lillian Mitchell bought a total of 2,000 shares at an average price of $0.88.</li>
<li>Douglas Elliman Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOUG#NYSE">DOUG</a>) climbed 23% to $1.66.</li>
<li>CareMax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) rose 19% to $6.71.</li>
<li>Liberty Broadband Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LBRDA#NASDAQ">LBRDA</a>) rose 17.6% to $65.16.</li>
<li>Charter Communications, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CHTR#NASDAQ">CHTR</a>) jumped 17% to $368.65 after the company reported better-than-expected second-quarter financial results.</li>
<li>Mohawk Industries, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MHK#NYSE">MHK</a>) gained 16.5% to $156.70 following mixed second-quarter earnings.</li>
<li>Karooooo Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KARO#NASDAQ">KARO</a>) gained 16% to $33.40. Karooooo announced termination of secondary public offering of ordinary shares due to market conditions.</li>
<li>3M Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMM#NYSE">MMM</a>) climbed 15% to $118.99 after better-than-expected second-quarter financial results and FY24 EPS outlook raise.</li>
<li>International Game Technology PLC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IGT#NYSE">IGT</a>) gained 13.4% to $22.86 after the company entered an agreement for its Gaming &amp; Digital business to be acquired by funds managed by affiliates of Apollo.</li>
<li>Altice USA, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ATUS#NYSE">ATUS</a>) rose 12.1% to $1.76.</li>
<li>Stardust Power Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SDST#NASDAQ">SDST</a>) rose 11% to $15.06.</li>
<li>Avantor, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AVTR#NYSE">AVTR</a>) surged 11% to $25.32 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Norfolk Southern Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSC#NYSE">NSC</a>) gained 10.7% to $246.86 after the company reported better-than-expected second-quarter earnings results.</li>
<li>Selina Hospitality PLC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SLNA#NASDAQ">SLNA</a>) shares gained 10.4% to $0.0415 after falling over 17% on Thursday.</li>
<li>Viasat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VSAT#NASDAQ">VSAT</a>) rose 9% to $20.58. Viasat announced new reporting segment structure.</li>
<li>Deckers Outdoor Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DECK#NYSE">DECK</a>) shares gained 8.7% to $914.71 as the company reported better-than-expected results for the first quarter. The company said it still expects net sales to increase approximately 10% year-over-year in fiscal year 2025 to $4.7 billion.</li>
<li>Bristol-Myers Squibb Company (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMY#NYSE">BMY</a>) climbed 7.6% to $48.69 following strong second-quarter earnings and increased 2024 guidance.</li>
<li>Centene Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNC#NYSE">CNC</a>) climbed 7.6% to $72.55 following better-than-expected second-quarter financial results and increased 2024 guidance.</li>
<li>Columbia Banking System, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) rose 7.4% to $25.98 after the company reported better-than-expected quarterly earnings results. Also, multiple firms raised their respective price targets on its stock.</li>
<li>Aon plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AON#NYSE">AON</a>) gained 6.8% to $319.30 after the company reported better-than-expected quarterly revenue results.</li>
<li>Ultra Clean Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UCTT#NASDAQ">UCTT</a>) shares gained 4.7% to $47.26 following better-than-expected quarterly results.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>NovaBay Pharmaceuticals, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NBY#NYSE">NBY</a>) shares dipped 59.6% to $0.7830 after the company reported pricing of $3.5 million underwritten public offering.</li>
<li>Tantech Holdings Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TANH#NASDAQ">TANH</a>) fell 46.9% to $0.2603.</li>
<li>Nature&#8217;s Miracle Holding Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NMHI#NASDAQ">NMHI</a>) fell 46.4% to $0.2099 after the company announced pricing of $1.2 million public offering.</li>
<li>DexCom, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DXCM#NASDAQ">DXCM</a>) shares declined 40.7% to $63.97 after the company reported worse-than-expected second-quarter revenue results and issued weak FY24 revenue guidance.</li>
<li>Predictive Oncology Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) fell 29.6% to $1.3150. Predictive Oncology announced exercise of warrants for $1.26 million gross proceeds.</li>
<li>ProMIS Neurosciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PMN#NASDAQ">PMN</a>) declined 29.2% to $1.5006 as the company reported top-line data from its Phase 1a Alzheimer&#8217;s trial and announced up to $122.7 million private placement financing.</li>
<li>PS International Group Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PSIG#NASDAQ">PSIG</a>) dipped 26.1% to $1.53</li>
<li>Grom Social Enterprises, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GROM#NASDAQ">GROM</a>) fell 23.8% to $0.2751.</li>
<li>Ocean Power Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPTT#NASDAQ">OPTT</a>) shares declined 23.2% to $0.3188 after reporting fourth-quarter results.</li>
<li>Avinger, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVGR#NASDAQ">AVGR</a>) fell 20.2% to $1.30.</li>
<li>Next Technology Holding Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXTT#NASDAQ">NXTT</a>) declined 20.1% to $1.6299.</li>
<li>Zynex, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYXI#NASDAQ">ZYXI</a>) shares fell 18.9% to $8.27 after the company reported worse-than-expected second-quarter financial results.</li>
<li>2U, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TWOU#NASDAQ">TWOU</a>) declined 17.6% to $1.24.</li>
<li>Ur-Energy Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/URG#NYSE">URG</a>) shares dipped 13.4% to $1.1250 after the company announced a proposed public offering of common shares.</li>
<li>BJ&#8217;s Restaurants, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BJRI#NASDAQ">BJRI</a>) fell 12.6% to $32.53 following quarterly results.</li>
<li>Booz Allen Hamilton Holding Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) declined 11.8% to $135.36 following a first-quarter earnings miss and soft EPS guidance.</li>
<li>Advent Technologies Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADN#NASDAQ">ADN</a>) shares fell 11.2% to $4.40 after gaining 3% on Thursday.</li>
<li>Tarsus Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TARS#NASDAQ">TARS</a>) fell 9.1% to $25.67.</li>
<li>World Acceptance Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WRLD#NASDAQ">WRLD</a>) dipped 7.8% to $134.62 following weak quarterly sales.</li>
<li>Forward Air Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FWRD#NASDAQ">FWRD</a>) fell 7.4% to $25.61.</li>
<li>Olin Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/OLN#NYSE">OLN</a>) shares declined 7.2% to $44.56 following a second-quarter earnings miss.</li>
<li>Carter&#8217;s, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRI#NYSE">CRI</a>) shares fell 6.6% to $55.87 following weak quarterly sales.</li>
<li>Biogen Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) declined 6.3% to $213.01 after the European Medicines Agency adopted a negative opinion on the Marketing Authorization Approval for lecanemab.</li>
<li>Tandem Diabetes Care, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNDM#NASDAQ">TNDM</a>) shares fell 6% to $38.18. Tandem Diabetes Care will release its second quarter results after the closing bell on Thursday, Aug. 1.</li>
<li>L3Harris Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LHX#NYSE">LHX</a>) declined 4.6% to $232.05 following second-quarter results.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/24/07/39984491/nvidia-lockheed-martin-and-2-other-stocks-insiders-are-selling">Nvidia, Lockheed Martin And 2 Other Stocks Insiders Are Selling</a></li>
</ul>

AEYE

ATUS

AVGR

AVTR

BIIB

BJRI

CHTR

CMAX

COLB

CREV

DECK

DOUG

EVRI

FWRD

GROM

KARO

KITT

LBRDA

Next Technology Holding Inc. - Ordinary Shares

NXTT

OPTT

PAPL

POAI

PSIG

SAIA

SDST

SGMO

SLNA

TANH

TARS

TNDM

TWOU

UCTT

VSAT

WRLD

ZYXI

Why Saia Shares Are Trading Lower? Here Are Other Stocks Moving In Friday's Mid-Day Session

NovaBay Pharmaceuticals shares are trading lower after the company priced a public offering of 3.2M shares and warrants at $1.10 per share.

Legal

Press Releases

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COFS, ARC, NBY, RFL on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BTTR, NBY, ARC on Behalf of Shareholders

NovaBay Pharmaceuticals Board Determines Unsolicited Offer is Superior to Asset Purchase Agreement with PRN Physician Recommended Nutriceuticals, LLC

NovaBay Pharmaceuticals Accepts Revised Offer from PRN Physician Recommended Nutriceuticals, LLC and Enters into an Amendment to the Asset Purchase Agreement to Increase Purchase Price

NovaBay Pharmaceuticals Reports Third Quarter 2024 Financial Results

Prominent Independent Proxy Advisory Firm ISS Supports NovaBay Pharmaceuticals' Proposals to Authorize the Sale of its Avenova Brand

NovaBay Pharmaceuticals to Reconvene Special Meeting of Stockholders on December 18, 2024

NovaBay CEO Letter to Stockholders Urges a FOR Vote at Upcoming Reconvened Special Meeting

NovaBay Pharmaceuticals Announces the Further Adjournment of the Special Meeting of Stockholders

NovaBay Pharmaceuticals Completes the Sale of its Eyecare Business to PRN and Further Adjourns its Special Meeting of Stockholders on Dissolution Proposal

Comments

NovaBay Pharmaceuticals

NovaBay Pharmaceuticals (NBY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga